Glycylpressin

Glycylpressin is a pharmaceutical product containing the active ingredient terlipressin acetate, supplied as an injectable solution for intravenous administration. It is classified as a vasopressin analog and is marketed in the European Union as a prescription‑only medication. The formulation is designed to provide controlled vasoconstriction for specific clinical situations, following established dosing protocols under medical supervision. It is intended for use only by qualified healthcare professionals in hospital settings.

Glycylpressin is employed in acute care to manage conditions where rapid reduction of portal pressure or systemic vasodilation is required. Its vasoconstrictive properties make it useful in several serious hepatic and circulatory disorders.

- Control of acute variceal bleeding in patients with cirrhosis. - Management of hepatorenal syndrome to improve renal perfusion. - Adjunctive therapy for refractory septic shock when other vasopressors are insufficient. - Temporary reduction of portal venous pressure prior to endoscopic or radiologic interventions. - Off‑label use in selected cases of severe hypotension unresponsive to standard agents.

The safety profile of Glycylpressin reflects its potent vasoconstrictive activity; side effects are reported across a spectrum from mild to potentially serious.

Common: - Headache or facial flushing. - Nausea or mild abdominal discomfort. - Transient hypertension with elevated systolic blood pressure. - Peripheral edema or mild swelling of extremities.

Serious: - Severe hypertension leading to hypertensive crisis. - Cardiac arrhythmias, including tachycardia or bradycardia. - Ischemic complications such as myocardial infarction or limb ischemia. - Acute respiratory distress due to pulmonary edema.

Because Glycylpressin induces marked vasoconstriction, careful patient assessment and monitoring are essential before and during therapy.

- Avoid use in patients with uncontrolled hypertension or recent myocardial infarction. - Assess cardiac function; contraindicated in severe heart failure or unstable angina. - Monitor serum electrolytes, especially potassium, as shifts may occur. - Use cautiously in patients with chronic kidney disease or active renal impairment. - Evaluate for signs of peripheral ischemia during infusion. - Discontinue promptly if severe hypertension or arrhythmia develops.

Glycylpressin can modify the effects of other cardiovascular agents, and certain drug combinations may increase the risk of adverse events.

Avoid: - Concurrent use with other potent vasopressors (e.g., norepinephrine, phenylephrine) without dose adjustment. - Combination with vasodilators such as nitroglycerin or hydralazine that may counteract therapeutic effect.

Use with caution: - Beta‑blockers, which may mask tachycardia while hypertension persists. - Diuretics that can exacerbate electrolyte disturbances, especially hypokalemia. - ACE inhibitors or ARBs, as they may influence renal perfusion during therapy.